CHOLESTOSOMES Trademark

Trademark Overview


On Wednesday, October 3, 2018, a trademark application was filed for CHOLESTOSOMES with the United States Patent and Trademark Office. The USPTO has given the CHOLESTOSOMES trademark a serial number of 88141769. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 6, 2022. This trademark is owned by Therasyn Sensors, Inc.. The CHOLESTOSOMES trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheim...
cholestosomes

General Information


Serial Number88141769
Word MarkCHOLESTOSOMES
Filing DateWednesday, October 3, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 6, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 10, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 12, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTherasyn Sensors, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBuffalo, NY 142263246

Party NameTherasyn Sensors, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBuffalo, NY 142263246

Trademark Events


Event DateEvent Description
Monday, June 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 6, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, January 18, 2022ASSIGNED TO EXAMINER
Saturday, November 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 4, 2021SOU EXTENSION 4 GRANTED
Thursday, November 4, 2021SOU EXTENSION 4 FILED
Thursday, November 4, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, April 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 26, 2021SOU EXTENSION 3 GRANTED
Monday, April 26, 2021SOU EXTENSION 3 FILED
Monday, April 26, 2021SOU TEAS EXTENSION RECEIVED
Saturday, October 31, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 29, 2020SOU EXTENSION 2 GRANTED
Thursday, October 29, 2020SOU EXTENSION 2 FILED
Thursday, October 29, 2020SOU TEAS EXTENSION RECEIVED
Friday, May 1, 2020ASSIGNED TO EXAMINER
Tuesday, April 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 17, 2020SOU EXTENSION 1 GRANTED
Friday, April 17, 2020SOU EXTENSION 1 FILED
Friday, April 17, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 10, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 10, 2019PUBLISHED FOR OPPOSITION
Wednesday, August 21, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, August 4, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 29, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 29, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 23, 2019ASSIGNED TO LIE
Thursday, July 18, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 22, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 22, 2019NON-FINAL ACTION E-MAILED
Tuesday, January 22, 2019NON-FINAL ACTION WRITTEN
Tuesday, January 15, 2019ASSIGNED TO EXAMINER
Friday, October 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, October 6, 2018NEW APPLICATION ENTERED